Exacerbations in Asthma and COPD: A GINA & GOLD Guideline Quiz

Article

Exacerbations of asthma and COPD have a negative impact on disease process in both conditions. Find out what you know about guideline-recommended mitigation.

Guidelines on management of both asthma and COPD strongly encourage medication adherence and trigger avoidance to reduce risk of disease exacerbation. In COPD, exacerbations are believed to hasten loss of lung function and prevention of exacerbations is now an important outcome measure in studies of new therapeutics in both diseases.

Answers to the 4 questions that follow are based on evidence-based guidelines from the Global Initiative for Asthma and the Global Initiative for Chronic Obstructive Lung Disease.

Recent Videos
Tezepelumab Significantly Reduced Exacerbations in Patients with Severe Asthma, Respiratory Comorbidities
Related Content
Weight Cycling Ups Risk for Heart Failure by 50%, Other Metabolic Diseases by Up to 30%: New Data

Weight Cycling Ups Risk for Heart Failure by 50%, Other Metabolic Diseases by Up to 30%: New Data

Grace Halsey
June 23rd 2025
Article

Weight cycling significantly raises heart failure and metabolic disease risks, independent of baseline overweight, underscoring the importance of stable weight strategies.

NAVIGATOR: Tezepelumab Reduces Asthma Exacerbations by More than Half

NAVIGATOR: Tezepelumab Reduces Asthma Exacerbations by More than Half

Sydney Jennings
May 20th 2022
Podcast

In our latest podcast episode, Njira Lugogo, MD, discusses NAVIGATOR data she presented at ATS 2022 that showed clinical responses to treatment with tezepelumab.

Rademikibart Demonstrates Improved Lung Function, Reduced Exacerbations in People with Eosinophilic-Driven Type 2 Asthma

Rademikibart Demonstrates Improved Lung Function, Reduced Exacerbations in People with Eosinophilic-Driven Type 2 Asthma

Sydney Jennings
June 17th 2025
Article

EAACI 2025. New data revealed the effectiveness of rademikibart in improving lung function and reducing asthma exacerbations in patients with eosinophilic-driven type 2 asthma.

Site Logo

Eternal Springs

Faith T. Fitzgerald, MD
January 13th 2010
Podcast

Doctors, especially primary care doctors, love stories. We love hearing them from patients and telling them to one another. “Anecdotal learning” it’s called by some (somewhat derisively because it’s not science).

Dupilumab Outperforms Omalizumab in First Head-to-Head Respiratory Study for CRSwNP with Comorbid Asthma

Dupilumab Outperforms Omalizumab in First Head-to-Head Respiratory Study for CRSwNP with Comorbid Asthma

Grace Halsey
June 16th 2025
Article

The phase 4 EVEREST study showed statistically significant improvements in polyp size reduction and smell identification ability as early as 4 weeks of treatment.

Clesrovimab Wins FDA Approval for Prevention of RSV LRTD in Infants During first RVS Season image credit ©Waldenmarus/stock.adobe.com

Clesrovimab Wins FDA Approval for Prevention of RSV LRTD in Infants During First RSV Season

Grace Halsey
June 10th 2025
Article

The preventive monoclonal antibody is designed to protect infants against RSV infection through 5 months and is administered at the same dose, regardless of weight.

© 2025 MJH Life Sciences

All rights reserved.